NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03180736 : Phase 3 - EMN 14 - Pomalidomide and Dexa +/- Dara in relapsed MM - APOLLO study
NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency
NCT01998971: Phase 1 - JNJ-54767414 (HuMax CD38) (Anti-CD38 Mono. Ab. ) in Myeloma EQUULEUS; MMY1001
NCT01946477: Phase 2 -Pomalidomide Combination With Low-dose Dex +/- Dara in RRMM Myeloma POM MM 014
NCT01754402: Phase 1 / 2 - Bendamustine + Pomalidomide + Dex in Relapsed Multiple Myeloma
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS